Nationwide practice in CT-based preoperative staging of colon cancer and concordance with definitive pathology.

Eur J Surg Oncol

Department of Surgery, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands; Department of Surgery, Meander Medical Centre, Maatweg 3, 3813 TZ, Amersfoort, the Netherlands. Electronic address:

Published: October 2023

AI Article Synopsis

  • * Results showed that the completeness of T-stage information improved significantly over time, but many cases still experienced misclassifications, with low sensitivity for certain tumor stages.
  • * Overall, while the ability to stage colon cancer has gotten better, inconsistencies remain, particularly in differentiating between stages, indicating the need for improved accuracy in diagnosing patients.

Article Abstract

Introduction: In an era of exploring patient-tailored treatment options for colon cancer, preoperative staging is increasingly important. This study aimed to evaluate completeness and reliability of CT-based preoperative locoregional colon cancer staging in Dutch hospitals.

Materials And Methods: Patients who underwent elective oncological resection of colon cancer without neoadjuvant treatment in 77 Dutch hospitals were evaluated between 2011 and 2021. Completeness of T-stage was calculated for individual hospitals and stratified based on a 60% cut-off. Concordance between routine CT-based preoperative locoregional staging (cTN) and definitive pathological staging (pTN) was examined.

Results: A total of 59,558 patients were included with an average completeness of 43.4% and 53.4% for T and N-stage, respectively. Completeness of T-stage improved from 4.9% in 2011-2014 to 74.4% in 2019-2021. Median completeness for individual hospitals was 53.9% (IQR 27.3-80.5%) and were not significantly different between low and high-volume hospitals. Sensitivity and specificity for T3-4 tumours were relatively low: 75.1% and 76.0%, respectively. cT1-2 tumours were frequently understaged based on a low negative predictive value of 56.8%. Distinction of cT4 and cN2 disease had a high specificity (>95%), but a very low sensitivity (<50%). Positive predictive values of <60% indicated that cT4 and cN1-2 were often overstaged. Completeness and time period did not influence reliability of staging.

Conclusion: Completeness of locoregional staging of colon cancer improved during recent years and varied between hospitals independently from case volume. Discriminating cT1-2 from cT3-4 tumours resulted in substantial understaging and overstaging, additionally cT4 and cN1-2 were overstaged in >40% of cases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2023.05.016DOI Listing

Publication Analysis

Top Keywords

colon cancer
16
ct-based preoperative
12
preoperative staging
8
preoperative locoregional
8
completeness t-stage
8
individual hospitals
8
staging
5
completeness
5
nationwide practice
4
practice ct-based
4

Similar Publications

Knockdown of LAMA3 enhances the sensitivity of colon cancer to oxaliplatin by regulating the Hippo-YAP pathway.

Biochim Biophys Acta Mol Basis Dis

January 2025

Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou City, Guangdong Province 510280, China. Electronic address:

Background: Oxaliplatin is the first-line chemotherapy for patients with colon cancer (CC). However, its resistance limits its therapeutic efficacy.

Methods: Oxaliplatin resistance-associated differentially expressed genes (DEGs) in the GSE42387 and GSE227315 datasets were identified through bioinformatics methods.

View Article and Find Full Text PDF

Polysaccharides from maggot extracts suppress colorectal cancer progression by inducing ferroptosis via HMOX1/GPX4 signaling pathway.

Int J Biol Macromol

January 2025

the Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing 210009, China; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, 42 Baiziting Road, Xuanwu District, Nanjing 210009, China. Electronic address:

Maggots contain various kinds of polysaccharides and recent studies mostly concentrated on their anti-inflammatory functions. While the molecule mechanisms related to the polysaccharides inhibiting carcinogenesis remains unclear. Here we characterized the polysaccharides extracted from maggot (MEs) determining their anti-colon cancer potentials.

View Article and Find Full Text PDF

Colon cancer is a leading cause of cancer-related morbidity and mortality worldwide, necessitating advancements in therapeutic strategies to improve outcomes. Current treatment modalities, including surgery, chemotherapy, and radiation, are limited by systemic toxicity, low drug utilization rates, and off-target effects. Colon-targeted drug delivery systems (CDDS) offer a promising alternative by leveraging the colon's unique physiology, such as near-neutral pH and extended transit time, to achieve localized and controlled drug release.

View Article and Find Full Text PDF

Background And Purpose: Cancer is one of the most prevalent diseases in the general population, and is one of the main causes of changes in the population's illness profile. In this study, we assessed changes in the functional status and quality of life of patients in the first months of chemotherapy treatment.

Method: A prospective cohort study was carried out, collecting data from cancer patients seen at an outpatient clinic in the Midwest of Santa Catarina who had breast, lung, colon and rectum, prostate and head and neck cancer.

View Article and Find Full Text PDF

'Pseudokidney' And 'Donut' signs of Colon cancer on Point-of-Care Ultrasound.

QJM

January 2025

Gastroenterology Unit, Department of Medicine, RIPAS Hospital, Jalan Putera Al-Muhtadee Billah, Bandar Seri Begawan, BA1712, Brunei Darussalam.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!